June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
April 2021 in “Journal of Investigative Dermatology”
4 citations
,
May 2019 in “Asian Journal of Pharmaceutical Sciences” Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression in people with alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
August 2023 in “European journal of dermatology/EJD. European journal of dermatology” Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
Suppressing ODC activity reduces tumor growth in hair follicles.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
March 2023 in “Reactions Weekly”
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
1 citations
,
January 2023 in “Cutis” You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
July 2025 in “Journal of Investigative Dermatology”
March 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Minoxidil treatment improves heart defects in a DiGeorge syndrome model.
7 citations
,
March 2025 in “Cytotechnology”
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.